{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:30:31Z","timestamp":1754145031910,"version":"3.41.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,16]]},"DOI":"10.7759\/cureus.88055","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:28:03Z","timestamp":1752658083000},"source":"Crossref","is-referenced-by-count":0,"title":["Improving the Response of High-Grade Glioma (HGG) Cells to Temozolomide Treatment Through Combination With Imatinib"],"prefix":"10.7759","author":[{"given":"Georgiana-Adeline","family":"Staicu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Costachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefana Oana","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan-Alexandru","family":"Artene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Elise","family":"Tache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond Nicolae","family":"Barcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea Denisa","family":"Hodorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anica","family":"Dricu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.17879\/freeneuropathology-2022-3804","article-title":"Neurooncology: 2022 update","volume":"3","author":"Wesseling P","year":"2022","unstructured":"Wesseling P, Rozowsky JS. Neurooncology: 2022 update. Free Neuropathol. 2022, 3:4. 10.17879\/freeneuropathology-2022-3804","journal-title":"Free Neuropathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03844-1","article-title":"(18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III\/IV glioma: moving towards a multimodal imaging-guided resection","volume":"155","author":"Ort J","year":"2021","unstructured":"Ort J, Hamou HA, Kernbach JM, et al.. (18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III\/IV glioma: moving towards a multimodal imaging-guided resection. J Neurooncol. 2021, 155:71-80. 10.1007\/s11060-021-03844-1","journal-title":"J Neurooncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214224","article-title":"Glioma stem cells: novel data obtained by single-cell sequencing","volume":"23","author":"Gisina A","year":"2022","unstructured":"Gisina A, Kholodenko I, Kim Y, Abakumov M, Lupatov A, Yarygin K. Glioma stem cells: novel data obtained by single-cell sequencing. Int J Mol Sci. 2022, 23:14224. 10.3390\/ijms232214224","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2020.09.003","article-title":"Intraoperative imaging for high-grade glioma surgery","volume":"32","author":"Noh T","year":"2021","unstructured":"Noh T, Mustroph M, Golby AJ. Intraoperative imaging for high-grade glioma surgery. Neurosurg Clin N Am. 2021, 32:47-54. 10.1016\/j.nec.2020.09.003","journal-title":"Neurosurg Clin N Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.02.025","article-title":"Imaging of intratumoral heterogeneity in high-grade glioma","volume":"477","author":"Hu LS","year":"2020","unstructured":"Hu LS, Hawkins-Daarud A, Wang L, Li J, Swanson KR. Imaging of intratumoral heterogeneity in high-grade glioma. Cancer Lett. 2020, 477:97-106. 10.1016\/j.canlet.2020.02.025","journal-title":"Cancer Lett"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2170","article-title":"Temozolomide (Temodar)","volume":"31","author":"Wesolowski JR","year":"2010","unstructured":"Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010, 31:1383-4. 10.3174\/ajnr.A2170","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14551","article-title":"Temozolomide based treatment in glioblastoma: 6 vs. 12 months","volume":"28","author":"Fasano M","year":"2024","unstructured":"Fasano M, Pirozzi M, De Falco V, et al.. Temozolomide based treatment in glioblastoma: 6 vs. 12 months. Oncol Lett. 2024, 28:418. 10.3892\/ol.2024.14551","journal-title":"Oncol Lett"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12865\/CHSJ.41.04.06","article-title":"Effect of VEGFR, PDGFR and PI3K\/mTOR targeting in glioblastoma","volume":"41","author":"Purcaru SO","year":"2015","unstructured":"Purcaru SO, Tache DE, Serban F, et al.. Effect of VEGFR, PDGFR and PI3K\/mTOR targeting in glioblastoma. Curr Health Sci J. 2015, 41:325-32. 10.12865\/CHSJ.41.04.06","journal-title":"Curr Health Sci J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong L","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, et al.. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021, 6:201. 10.1038\/s41392-021-00572-w","journal-title":"Signal Transduct Target Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38 Suppl 5","author":"Buchdunger E","year":"2002","unstructured":"Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002, 38 Suppl 5:S28-36. 10.1016\/s0959-8049(02)80600-1","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2022.05.004","article-title":"Dermatofibrosarcoma protuberans: what is this?","volume":"102","author":"Vitiello GA","year":"2022","unstructured":"Vitiello GA, Lee AY, Berman RS. Dermatofibrosarcoma protuberans: what is this?. Surg Clin North Am. 2022, 102:657-65. 10.1016\/j.suc.2022.05.004","journal-title":"Surg Clin North Am"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.1060012","article-title":"New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor \u03b1) based on computational study for high-grade glioma therapy","volume":"16","author":"Yang W","year":"2022","unstructured":"Yang W, Wang S, Zhang X, et al.. New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor \u03b1) based on computational study for high-grade glioma therapy. Front Neurosci. 2022, 16:1060012. 10.3389\/fnins.2022.1060012","journal-title":"Front Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-003","article-title":"Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma","volume":"10","author":"Reardon DA","year":"2008","unstructured":"Reardon DA, Desjardins A, Vredenburgh JJ, et al.. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008, 10:330-40. 10.1215\/15228517-2008-003","journal-title":"Neuro Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194663","article-title":"Platelet-derived growth factor receptor and ionizing radiation in high grade glioma cell lines","volume":"20","author":"Alexandru O","year":"2019","unstructured":"Alexandru O, Sevastre AS, Castro J, et al.. Platelet-derived growth factor receptor and ionizing radiation in high grade glioma cell lines. Int J Mol Sci. 2019, 20:4663. 10.3390\/ijms20194663","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209497","article-title":"Characterization of an imatinib-sensitive subset of high-grade human glioma cultures","volume":"25","author":"H\u00e4gerstrand D","year":"2006","unstructured":"H\u00e4gerstrand D, Hesselager G, Achterberg S, et al.. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene. 2006, 25:4913-22. 10.1038\/sj.onc.1209497","journal-title":"Oncogene"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou TC","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22:27-55. 10.1016\/0065-2571(84)90007-4","journal-title":"Adv Enzyme Regul"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2011.406","article-title":"Effect of temozolomide on the U-118 glioma cell line","volume":"2","author":"Carmo A","year":"2011","unstructured":"Carmo A, Carvalheiro H, Crespo I, Nunes I, Lopes MC. Effect of temozolomide on the U-118 glioma cell line. Oncol Lett. 2011, 2:1165-70. 10.3892\/ol.2011.406","journal-title":"Oncol Lett"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08972-5","article-title":"Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies","volume":"21","author":"Poon MT","year":"2021","unstructured":"Poon MT, Bruce M, Simpson JE, Hannan CJ, Brennan PM. Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies. BMC Cancer. 2021, 21:1240. 10.1186\/s12885-021-08972-5","journal-title":"BMC Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2020.94726","article-title":"Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches","volume":"24","author":"Alexandru O","year":"2020","unstructured":"Alexandru O, Horescu C, Sevastre AS, Cioc CE, Baloi C, Oprita A, Dricu A. Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. Contemp Oncol (Pozn). 2020, 24:55-66. 10.5114\/wo.2020.94726","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2015.56122","article-title":"New perspectives in glioblastoma antiangiogenic therapy","volume":"20","author":"Popescu AM","year":"2016","unstructured":"Popescu AM, Purcaru SO, Alexandru O, Dricu A. New perspectives in glioblastoma antiangiogenic therapy. Contemp Oncol (Pozn). 2016, 20:109-18. 10.5114\/wo.2015.56122","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010229","article-title":"The influence of EGFR inactivation on the radiation response in high grade glioma","volume":"19","author":"Alexandru O","year":"2018","unstructured":"Alexandru O, Purcaru SO, Tataranu LG, et al.. The influence of EGFR inactivation on the radiation response in high grade glioma. Int J Mol Sci. 2018, 19:229. 10.3390\/ijms19010229","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2012.01.014","article-title":"Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib","volume":"318","author":"Kinsella P","year":"2012","unstructured":"Kinsella P, Howley R, Doolan P, et al.. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. Exp Cell Res. 2012, 318:641-52. 10.1016\/j.yexcr.2012.01.014","journal-title":"Exp Cell Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme","volume":"23","author":"Reardon DA","year":"2005","unstructured":"Reardon DA, Egorin MJ, Quinn JA, et al.. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005, 23:9359-68. 10.1200\/JCO.2005.03.2185","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9302-2","article-title":"Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas","volume":"83","author":"Desjardins A","year":"2007","unstructured":"Desjardins A, Quinn JA, Vredenburgh JJ, et al.. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007, 83:53-60. 10.1007\/s11060-006-9302-2","journal-title":"J Neurooncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9976-3","article-title":"Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide","volume":"96","author":"Dresemann G","year":"2010","unstructured":"Dresemann G, Weller M, Rosenthal MA, et al.. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010, 96:393-402. 10.1007\/s11060-009-9976-3","journal-title":"J Neurooncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nop068","article-title":"Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies","volume":"12","author":"De Witt Hamer PC","year":"2010","unstructured":"De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol. 2010, 12:304-16. 10.1093\/neuonc\/nop068","journal-title":"Neuro Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/srep27378","article-title":"Imatinib and nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling","volume":"6","author":"Frolov A","year":"2016","unstructured":"Frolov A, Evans IM, Li N, et al.. Imatinib and nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling. Sci Rep. 2016, 6:27378. 10.1038\/srep27378","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071790","article-title":"ATRX-deficient high-grade glioma cells exhibit increased sensitivity to RTK and PDGFR inhibitors","volume":"14","author":"Pladevall-Morera D","year":"2022","unstructured":"Pladevall-Morera D, Castej\u00f3n-Gri\u00f1\u00e1n M, Aguilera P, et al.. ATRX-deficient high-grade glioma cells exhibit increased sensitivity to RTK and PDGFR inhibitors. Cancers (Basel). 2022, 14:1790. 10.3390\/cancers14071790","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-111","article-title":"Response to imatinib as a function of target kinase expression in recurrent glioblastoma","volume":"3","author":"Hassler MR","year":"2014","unstructured":"Hassler MR, Vedadinejad M, Flechl B, et al.. Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springerplus. 2014, 3:111. 10.1186\/2193-1801-3-111","journal-title":"Springerplus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372462-improving-the-response-of-high-grade-glioma-hgg-cells-to-temozolomide-treatment-through-combination-with-imatinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:28:04Z","timestamp":1752658084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372462-improving-the-response-of-high-grade-glioma-hgg-cells-to-temozolomide-treatment-through-combination-with-imatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.88055","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}